Check out our most popular compounded medications! Get Started
Bayview Pharmacy's Dihydroergotamine Mesylate 3 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects. This formulation is used to treat conditions such as migraine, cluster headache, Meniere's disease, post-traumatic headache, and tension headache. The slow release mechanism also reduces dosing frequency and improves patient compliance for medications requiring a controlled and prolonged release profile.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Dihydroergotamine Mesylate 3 mg Slow Release Capsules is a specialized prescription medication primarily used for the treatment of migraine headaches. It functions by constricting the blood vessels surrounding the brain, thereby alleviating the pain associated with migraines. This particular formulation is engineered with Methocel E4M, a type of controlled-release polymer, which ensures a gradual release of the encapsulated medication over an extended period. This slow-release mechanism allows for sustained therapeutic effects, reduced dosing frequency, and improved patient compliance, particularly beneficial for medications requiring a controlled and prolonged release profile.
However, this formulation is not recommended for all patients. Those with certain medical conditions, such as uncontrolled high blood pressure, ischemic heart disease, or peripheral vascular disease, should avoid this medication. Additionally, it is contraindicated for patients currently taking certain medications, including ergotamine, ergonovine, or methylergonovine. It is crucial that patients adhere strictly to the dosage and administration instructions provided by their healthcare provider to avoid potential serious side effects.
Common side effects of Dihydroergotamine Mesylate 3 mg Slow Release Capsules include nausea, vomiting, dizziness, and drowsiness. However, these side effects are generally manageable and should subside as the body adjusts to the medication. If these side effects persist or worsen, patients should immediately consult their healthcare provider.
At Bayview Pharmacy, we are committed to providing our patients with this advanced formulation of Dihydroergotamine Mesylate 3 mg Slow Release Capsules. We encourage patients to reach out to us with any questions or concerns regarding this medication or its use. Our team is always ready to provide the necessary guidance and support to ensure optimal patient care and satisfaction.
Dihydroergotamine Mesylate 3 mg Slow Release Capsules are a specialized formulation designed for the treatment of migraine headaches, cluster headaches, and other vascular headaches. This formulation utilizes Methocel E4M, a controlled-release polymer, to gradually release the encapsulated medication over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance, making it an ideal choice for medications requiring a controlled and prolonged release profile.
It is crucial to note that this formulation is not intended for the treatment of other types of headaches, such as tension headaches, nor should it be used to treat any other medical conditions. Patients should be aware of potential interactions with other medications they may be taking, including ergot alkaloids, macrolide antibiotics, HIV protease inhibitors, serotonin reuptake inhibitors, and certain antifungal medications. Additionally, this formulation may interact with certain foods, such as aged cheeses, red wine, and certain types of fish.
Patients should also be aware that this formulation may cause side effects such as drowsiness, dizziness, and blurred vision. It is advised not to drive or operate machinery until the effects of this medication are fully understood. Prescribers should also be aware of these potential interactions and side effects when considering this formulation for their patients.
If you have any questions about the interactions or side effects of Dihydroergotamine Mesylate 3 mg Slow Release Capsules, please do not hesitate to reach out for further information.
Dihydroergotamine Mesylate 3 mg Slow Release Capsules are a specialized formulation designed to treat various types of headaches, including migraines and cluster headaches. The active ingredient, Dihydroergotamine Mesylate, functions by constricting the blood vessels in the brain, reducing inflammation, and inhibiting the release of certain natural substances that trigger pain. This medication also aids in alleviating associated symptoms such as nausea and sensitivity to light and sound.
This particular formulation employs Methocel E4M, a controlled-release polymer, to encapsulate the medication. This design ensures a gradual and sustained release of the active ingredient over an extended period, providing a steady therapeutic effect. This slow-release mechanism reduces the need for frequent dosing and enhances patient compliance, particularly beneficial for medications requiring a controlled and prolonged release profile.
When using Dihydroergotamine Mesylate 3 mg Slow Release Capsules, adherence to the prescribed instructions is crucial. The capsules should be consumed with food or milk to minimize the potential for stomach upset. Consistency in the timing of dosage is also important to maintain a steady level of medication in the body. It is advised to abstain from alcohol while on this medication, as it may heighten the risk of side effects.
Side effects such as nausea, vomiting, dizziness, drowsiness, and dry mouth may occur. In the event of experiencing any side effects, immediate contact with a healthcare professional is recommended. This formulation is designed with patient safety and efficacy in mind, and any concerns or queries regarding its use should be directed to a healthcare provider.
Dihydroergotamine Mesylate 3 mg Slow Release Capsules are a specialized formulation designed to gradually release the active ingredient over an extended period. This is achieved through the use of Methocel E4M, a controlled-release polymer. The slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications that require a controlled and prolonged release profile.
While primarily used for the treatment of migraines, Dihydroergotamine Mesylate 3 mg Slow Release Capsules have also been used off-label for the management of other headache disorders. These include chronic daily headache, hemicrania continua, and new daily persistent headache. Additionally, it has been utilized to alleviate symptoms such as vertigo, nausea, and vomiting that are often associated with migraines.
Furthermore, Dihydroergotamine Mesylate 3 mg Slow Release Capsules may serve as a prophylactic treatment for a variety of conditions. These include migraine, cluster headache, Meniere's Disease, post-traumatic headache, and tension headache.
Patients considering this formulation for off-label uses should engage in a thorough discussion of the potential risks and benefits with their healthcare provider. If you have any questions or concerns about the use of Dihydroergotamine Mesylate 3 mg Slow Release Capsules for any of these conditions, it is recommended that you seek professional medical advice.
Dihydroergotamine Mesylate 3 mg Slow Release Capsules is a medication formulated with Methocel E4M, a type of controlled-release polymer. This formulation is designed to gradually release the active ingredient over an extended period of time.
The controlled-release polymer, Methocel E4M, is designed to release the encapsulated medication gradually over an extended period of time. This offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance for medications requiring a controlled and prolonged release profile.
A slow-release formulation offers several benefits. It provides sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, especially for medications that require a controlled and prolonged release profile.
The slow-release mechanism works by gradually releasing the active ingredient over an extended period of time. This is achieved through the use of a controlled-release polymer, Methocel E4M, which encapsulates the medication.
'Improved patient compliance' means that patients are more likely to take their medication as prescribed. This is because the slow-release formulation reduces the frequency of dosing, making it easier for patients to adhere to their medication regimen.
Methocel E4M is a type of controlled-release polymer. It is used in the formulation of certain medications to encapsulate the active ingredient and release it gradually over an extended period of time.
'Sustained therapeutic effects' means that the medication continues to have its intended effect over a longer period of time. This is achieved through the slow-release formulation, which gradually releases the active ingredient.
The frequency of dosing will depend on your doctor's instructions. However, the slow-release formulation is designed to reduce the frequency of dosing, making it easier for you to take your medication as prescribed.
No, the capsule should not be opened. The medication is encapsulated in a controlled-release polymer, which is designed to gradually release the active ingredient over an extended period of time. Opening the capsule could interfere with this mechanism.
If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses. Always consult your healthcare provider to ensure the information provided applies to your personal circumstances.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
